Body composition phenotypes in systemic lupus erythematosus and rheumatoid arthritis: A comparative study of Caucasian female patients

Clinical and Experimental Rheumatology

Volumn 29, Issue 3, 2011, Pages 470-476

  Santos, Maria José ^a,b   Vinagre, F ^b   Canas Da Silva, J ^b   Gil, V ^a,c   Fonseca, J E ^a,d  

^a UNIVERSITY OF LISBON   (Portugal)

^b HOSPITAL GARCIA DE ORTA   (Portugal)

^c HOSPITAL FERNANDO FONSECA   (Portugal)

^d HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Inflammation; Obesity; Rheumatoid arthritis; Sarcopenia; Systemic lupus erythematosus

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MUSCLE ATROPHY; OBESITY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; WAIST CIRCUMFERENCE; ABDOMINAL OBESITY; CAUCASIAN; INCIDENCE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ADULT; ARTHRITIS, RHEUMATOID; BODY COMPOSITION; BODY MASS INDEX; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; OBESITY, ABDOMINAL; PHENOTYPE; RISK FACTORS; SARCOPENIA; WAIST CIRCUMFERENCE;

EID: 80052052793     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. GULSVIK A.K., THELLE D.S., MOWÉ M., WYLLER T.B.: Increased mortality in the slim elderly: A 42 years follow-up study in a general population. Eur J Epidemiol 2009; 24: 683-690
2. PEEERS A., BARENDREGT J.J., WILLEKENS F., MACKENBACH J.P., ALMAMUN A., BONNEAUX L.; NEDCOM, THE NETHERLANDS EPIDEMIOLOGY AND DEMOGRAPHY COMPRESSION OF MORBIDITY RESEARCH GROUP: Obesity in adulthood and its consequences for life expectancy: A life-table analysis. Ann Int Med 2003; 138: 24-32.
3. OESER A., CHUNG C.P., ASANUMA Y., AVALOS I., STEIN C.M.: Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 2005; 11: 3651-3659
4. GARCIA-POMA A., SEGAMI M.I., MORA C.S. et al.: Obesity is independently associated with impaired quality of life in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26: 1831-1835
5. HONG Y., JIN X., MO J. et al.: Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality - results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med 2007; 262: 113-122
6. SANTOS M.J., FONSECA J.E.: Metabolic syndrome, inflammation and atherosclerosis - The role of adipokines in health and in systemic inflammatory rheumatic diseases. Acta Reumatol Port 2009; 34: 590-598
7. RIDKER P.M., BURING J.E., COOK N.R., RIFAI N.: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-397
8. SOKKA T., HÄKKINEN A., KAUTIAINEN H. et al.: Physical inactivity in patients with Rheumatoid Arthritis: Data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum 2008; 59: 42-50.
9. MOK C.C., TO C.H., MA K.M.: Changes in body composition after glucocorticoid therapy in patients with systemic lupus erythematosus. Lupus 2008; 17: 1018-1022
10. GILES J.T., LING S.M., FERRUCCI L. et al.: Abnormal body composition phenotypes in older Rheumatoid Arthritis patients: Association with disease characteristics and pharmacotherapies. Arthritis Rheum 2008; 59: 807-815
11. ELKAN A.C., ENGVALL I.L., CEDERHOLM T., HAFSTRÖM I.: Rheumatoid cachexia, central obesity and malnutrition in patients with low-active rheumatoid arthritis: Feasibility of anthropometry, Mini Nutritional assessment and body composition techniques. Eur J Nutr 2009; 48: 315-322
12. LILLEBY V., HAUGEN M., MØRKRID L., FREY FRØSLIE K., HOLVEN K.B., FØRRE O.: Body composition, lipid and lipoprotein levels in childhood-onset systemic lupus erythematosus. Scand J Rheumatol 2007; 36: 40-47
13. LUMINA STUDY GROUP: The impact of increased body mass index on systemic lupus erythematosus: Data from LUMINA, a multiethnic cohort. J Clin Rheumatol 2007; 13: 128-133
14. SANTOS M.J., VINAGRE F., CANAS DA SILVA J., GIL V., FONSECA J.E.: Cardiovascular risk profile in systemic lupus erythematosus and rheumatoid arthritis: A comparative study of female patients. Acta Reumatol Port 2010; 35: 325-332
15. PEREIRA R.M., DE CARVALHO J.F., BONFÁ E.: Metabolic syndrome in rheumatological diseases. Autoimmun Rev 2009; 8: 415-419
16. GLADMAN D.D., IBAÑEZ D., UROWITZ M.B.: Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291
17. GLADMAN D., GINZLER E., GOLDSMITH C. et al.: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369
18. PREVO M.L., VAN' T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48
19. FRIES J.F., SPITZ P., KRAINES R.G., HOLMAN H.R.: Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-145
20. WORLD HEALTH ORGANIZATION: Obesity: Preventing and Managing the Global Epidemic: Report on a WHO Consultation (WHO Technical Report Series 894). Geneva, Switzerland: World Health Organization; 2000.
21. http://www.idf.org/webdata/docs/MetS-def-update2006.pdf
22. DAVISON K.K., FORD E.S., COGSWELL M.E., DIETZ W.H.: Percentage of body fat and body mass index are associated with mobility limitations in people aged 70 and older from NHANES III. J Am Geriatr Soc 2002; 50: 1802-1809
23. SCHUTZ Y., KYLE U.U.G., PICHARD C.: Fat-free mass index and fat mass index percentiles in Caucasians aged 18-98 y. Int J Obes 2002; 26: 953-960
24. LEAR S.A., KOHLI S., BONDY G.P., TCHERNOF A., SNIDERMAN A.D.: Ethnic variation in fat and lean body mass and the association with insulin resistance. J Clin Endocrinol Metab 2009; 94: 4696-4702
25. STAVROPOULOS-KALINOGLOU A., METSIOS G.S., KOUTEDAKIS Y. et al: Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007; 66: 1316-1321
26. HAN T.S., MCNEILL G., SEIDELL J.C., LEAN M.E.: Predicting intra-abdominal fatness from anthropometric measures: The influence of stature. Int J Obes Relat Metab Disord 1997; 21: 587-589
27. DE KONING L., MERCHANT A.T., POGUE J., ANAND S.S.: Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: Meta-regression analysis of prospective studies Eur Heart J 2007; 28: 850-856
28. STRABURZYŃSKA-LUPA A., NOWAK A., PILACZYŃSKA- SZCZEŚNIAK Ł et al.: Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 19-24.
29. URSINI F., NATY S., GREMBIALE R.D.: Infliximab and insulin resistance. Autoimmun Rev 2010; 9: 536-539
30. GONZALEZ-GAY M.A., GARCIA-UNZUETA M.T., BERJA A. et al.: Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 222-228
31. GONZALEZ-GAY M.A., VAZQUEZ-RODRIGUEZ T.R., GARCIA-UNZUETA M.T. et al.: Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin Exp Rheumatol 2010; 28: 56-62.
32. ROUBENOFF R., ROUBENOFF R.A., WARD L.M., STEVENS M.B.: Catabolic effects of high-dose corticosteroids persist despite therapeutic benefit in rheumatoid arthritis. Am J Clin Nutr 1990; 52: 1113-1117
33. ROLLAND Y., LAWERS-CANCES V., CRISTINI C. et al.: Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: The EPIDOS Study. Am J Clin Nutr 2009; 89: 1895-1900
34. METSIOSG S., STAVROPOULOS-KALINOGLOU A., PANOULAS V.F. et al.: Rheumatoid cachexia and cardiovascular disease. Clin Exp Rheumatol 2009; 27: 985-988
35. YEH S.S., SCLUSTER M.W.: Geriatric cachexia: The role of cytokines. Am J Clin Nutr 1999; 70: 183-197
36. FANTINO M., WIETESKA L.: Evidence for a direct central anorectic effect of tumor-necrosis-factor-alpha in the rat. Physiol Behav 1993; 53: 477-483
37. STUDNICKA-BENKE A., STEINER G., PETERA P., SMOLEN J.S.: Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 1067-1074
38. SAXNE T., PALLADINO MA J.R., HEINEGARD D., TADAL N., WOLLHEIM F.A.: Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31: 1041-1045
39. ROUBENOFF R., ROUBENOFF R.A., CANNON J.G. et al.: Rheumatoid cachexia: Cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93: 2379-2386
40. ENGVALL I.L., ELKAN A.C., TENGSTRAND B., CEDERHOLM T., BRISMAR K., HAFSTROM I.: Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor. Scand J Rheumatol 2008; 37: 321-328
41. METSIOSG S., STRAVOPOULOS-KALINOGLOU A., DOUGLAS K.M.J. et al.: Blockade of tumour nectosis factor-α in rheumatoid arthritis: Effects on components of rheumatoid cachexia. Rheumatology 2007; 46: 1824-1827
42. FORBES G.B.: Perspectives on body composition. Curr Opin Clin Nutr Metab Care 2002; 5: 25-30.